CoVPN 3502/REGN 2069: Regeneron’s REGEN-COV Antibody Cocktail

Read the latest news releases:  

CoVPN 3502/REGN 2069 tested the combination of two antibodies’ (casirivimab and imdevimab antibody cocktail) ability to prevent acquisition of SARS-CoV-2. This study enrolled approximately 3,300 adults and adolescents in North America and Europe who shared a household with a person who recently tested positive for SARS-CoV-2.  

Volunteers could be SARS-CoV-2 negative at enrollment or have acquired SARS-CoV-2 but did not have any COVID-19 symptoms. The REGEN-COV antibody cocktail was designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. The REGEN-COV antibodies were made in a lab by the pharmaceutical company Regeneron. The REGEN-COV antibody cocktail cannot give you SARS-CoV-2, nor will it make you sick with COVID-19.

Learn more about the Regeneron monoclonal antibody clinical study and the antibodies used: 

Content last reviewed on June 12, 2021